Episode 32: t(11;14) Multiple Myeloma and Role of Venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser
Blood Cancer Talks · Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser.
Here are the shownotes:
1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma:
https://x.com/Rfonsi1/status/1206004966294294528?s=20
2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs:
https://pubmed.ncbi.nlm.nih.gov/28655925/
3. BELLINI trial (Ven-Bort-Dex vs Bort-Dex in all-comers):
https://pubmed.ncbi.nlm.nih.gov/33129376/
4. Efficacy of Dara-VCD by cytogenetic subgroups in AL Amyloidosis:
https://pubmed.ncbi.nlm.nih.gov/36779691/
5. CANOVA Trial (Ven-Dex vs Pom-Dex in t[11;14]):
https://www.clinical-lymphoma-myeloma-leukemia.com/issue/S2152-2650(23)X0011-1?pageStart=0
6. Phase 1/2 trial on Daratumumab-Venetoclax-Dex in Relapsed/Refractory Myeloma:
https://pubmed.ncbi.nlm.nih.gov/34388020/
7. Phase 1/2 trial on Venetoclax-Carfilzomib-Dex in relapsed/refractory myeloma:
https://pubmed.ncbi.nlm.nih.gov/34470049/